US Patent

US11311498 — Use of cannabinoids in the treatment of epilepsy

Method of Use · Assigned to GW Research Ltd · Expires 2035-06-17 · 9y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of cannabidiol (CBD) in treating absence seizures in patients with certain epilepsy-related conditions.

USPTO Abstract

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3375 — Epidiolex

Patent Metadata

Patent number
US11311498
Jurisdiction
US
Classification
Method of Use
Expires
2035-06-17
Drug substance claim
No
Drug product claim
No
Assignee
GW Research Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.